<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362361</url>
  </required_header>
  <id_info>
    <org_study_id>TRICC-C (AIO-KRK-0111)</org_study_id>
    <secondary_id>2010-023050-37</secondary_id>
    <nct_id>NCT01362361</nct_id>
  </id_info>
  <brief_title>TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)</brief_title>
  <acronym>AIO-KRK-0111</acronym>
  <official_title>TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GALMED GmbH, Halle, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study:

      To explore the comparative effectiveness of BIBF 1120 in terms of :

        -  Progression-free survival (PFS), objective response, overall survival

        -  Evaluate and compare safety
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mFOLFOX6 + BIBF 1120</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>mFOLFOX6+placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6 + BIBF 1120</intervention_name>
    <description>mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6+placebo</intervention_name>
    <description>mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven colorectal adenocarcinoma

          2. Intended treatment with mFOLFOX6 after one prior palliative chemotherapy for
             metastatic CRC

          3. Age &gt; 18 years

          4. Metastatic disease not suitable for curative-intent surgery

          5. Measurable (&gt; 1 cm) and evaluable disease (according to RECIST 1.1 criteria)

          6. Prior bevacizumab, cetuximab or panitumumab are allowed.

          7. Previous adjuvant oxaliplatin-containing therapy is allowed, if the end of adjuvant
             chemotherapy is &gt;12 months prior to inclusion into the trial

          8. ECOG performance status 0 or 1 (see appendix 10.4)

          9. Adequate hepatic function

         10. Adequate Renal function

         11. Adequate bone marrow function

         12. Other lab parameters: proteinuria &lt; CTCAE grade 2, Prothrombin time and/or partial
             thromboplastin time &lt; 50 % deviation from normal limits

         13. Life expectancy at least 3 months

         14. Signed and dated written informed consent prior to admission to the study in
             accordance with ICH-GCP guidelines and to the local legislation

        Exclusion Criteria:

          1. Known hypersensitivity to the trial drugs or their excipients.

          2. Treatment with any investigational drug within 28 days of trial onset.

          3. Prior treatment with more than one line of palliative standard chemotherapy for
             colorectal cancer, prior treatment with a tyrosine kinase inhibitor, prior palliative
             treatment with an oxaliplatin-containing regime.

          4. History of other malignancies in the last 5 years, in particular those which could
             affect compliance with the protocol or interpretation of results. Patients with
             adequately treated basal or squamous cell skin cancer are generally eligible.

          5. Serious concomitant disease, especially those that would limit compliance with trial
             requirements or which are considered relevant for the evaluation of the efficacy or
             safety of the trial drug, such as neurologic, psychiatric, infectious disease or
             active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may
             increase the risk associated with trial participation or trial drug administration,
             and in the judgment of the investigator would make the patient inappropriate for entry
             into the trial.

          6. Major injuries and/or surgery or bone fracture within 4 weeks of trial inclusion, or
             planned surgical procedures during the trial period. Portimplantation prior to therapy
             is allowed.

          7. Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina,
             history of infarction within past 9 months, congestive heart failure &gt; NYHA II) (see
             appendix 10.3).

          8. History of severe haemorrhagic or thrombotic events in the past 12 months (excluding
             central venous catheter thrombosis and peripheral deep vein thrombosis). Known
             inherited predisposition to bleeds or to thrombosis.

          9. Patient with brain metastases that are symptomatic and/or require therapy.

         10. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed
             for maintenance of an indwelling intravenous device) or antiplatelet therapy (except
             for chronic low-dose therapy with acetylsalicylic acid ≤ 325mg per day)

         11. History of major thrombotic or clinically relevant major bleeding event in the past 6
             months

         12. Current peripheral neuropathy ≥ CTCAE grade 2 except due to trauma

         13. Serious infections requiring systemic antibiotic (e.g antiviral, antimicrobial,
             antifungal) therapy

         14. Gastrointestinal disorders or abnormalities that would interfere with absorption of
             the study drug

         15. Active alcohol or drug abuse.

         16. Women and men who are sexually active and unwilling to use a medically acceptable
             method of contraception

         17. Pregnancy or breast-feeding

         18. Leptomeningeal disease

         19. Radiographic evidence of cavitary or necrotic tumours

         20. Centrally located tumours with radiographic evidence (CT or MRI) of local invasion of
             major blood vessels

         21. Severe chemotherapy-associated toxicity during or after adjuvant or palliative
             first-line chemotherapy like 5-FU-associated cardiac toxicity (coronary spasm) or
             persistent oxaliplatin-associated peripheral neuropathy (≥ CTCAE grade 2) with
             paresthesia associated with pain or functional impairment (after adjuvant
             oxaliplatin-containing chemotherapy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Seufferlein, MD</last_name>
    <phone>+49-345-557-2661</phone>
    <email>thomas.seufferlein@uk-halle.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Seufferlein, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Seufferlein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas J. Ettrich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Hämatologie und Onkologie Bottrop und Dorsten</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carla V. Hannig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Greifswald -Klinik für Innere Medizin A</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julia Mayerle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis und Tagesklinik Onkologie und Gastroenterologie - Halle</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefanie Frank-Gleich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Karlsruhe, Medizinische Klinik III</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margarethe Schmier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH - Krankenhaus Holweide</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudia Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim - TTZ am Interdisziplinären Tumorzentrum</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ralf Hofheinz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joh. Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans-Joachim Tischler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd - Mutlangen - Zentrum Innere Medizin</name>
      <address>
        <city>Mutlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Holger Hebart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München-Großhadern - Medizinische Klinik und Poliklink III</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Volker Heinemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leopoldina-Krankenhaus Schweinfurt - Medizinische Klinik 2</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephan Kanzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm - Klinik für Innere Medizin I</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Götz von Wichert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2011</study_first_submitted>
  <study_first_submitted_qc>May 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2011</study_first_posted>
  <last_update_submitted>April 5, 2012</last_update_submitted>
  <last_update_submitted_qc>April 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Thomas Seufferlein</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Second line colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

